Gujarat Themis Biosyn Ltd vs Supriya Lifescience Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Apr 04, 2026

Key Highlights

The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 251.5 as of 02 Apr 15:30 . The P/E Ratio of Gujarat Themis Biosyn Ltd changed from 9.8 on March 2021 to 62.8 on March 2025 . This represents a CAGR of 44.99% over 5 yearsThe P/E Ratio of Supriya Lifescience Ltd changed from 26.1 on March 2022 to 31.4 on March 2025 . This represents a CAGR of 4.73% over 4 years The Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 295.88 crore on March 2021 to ₹ 3067 crore on March 2025 . This represents a CAGR of 59.64% over 5 yearsThe Market Cap of Supriya Lifescience Ltd changed from ₹ 3967 crore on March 2022 to ₹ 5903 crore on March 2025 . This represents a CAGR of 10.45% over 4 years The revenue of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 43.78 crore as compare to the Sep '25 revenue of ₹ 43.17 crore. This represent the growth of 1.41% The revenue of Supriya Lifescience Ltd for the Dec '25 is ₹ 209.05 crore as compare to the Sep '25 revenue of ₹ 202.56 crore. This represent the growth of 3.2% The ebitda of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 21.72 crore as compare to the Sep '25 ebitda of ₹ 21.76 crore. This represent the decline of -0.18% The ebitda of Supriya Lifescience Ltd for the Dec '25 is ₹ 74.24 crore as compare to the Sep '25 ebitda of ₹ 75.37 crore. This represent the decline of -1.5% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 13.24 crore to ₹ 12.46 crore over 7 quarters. This represents a CAGR of -3.41% The net profit of Supriya Lifescience Ltd changed from ₹ 44.64 crore to ₹ 49.68 crore over 7 quarters. This represents a CAGR of 6.30% The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 yearsThe Dividend Payout of Supriya Lifescience Ltd changed from 3.2 % on March 2021 to 4.28 % on March 2025 . This represents a CAGR of 5.99% over 5 years .

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Supriya Lifescience Ltd

Supriya Lifescience Limited was initially constituted on October 29, 1985, as a 'Partnership Firm under the name M/s Supriya Chemicals'.
The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007.
Upon the conversion of M/s Supriya Chemicals' the Partnership Firm into a Public Limited Company, the Company got incorporated as Supriya Lifescience Limited' vide certified on March 26, 2008 by the Registrar of Companies, Mumbai. The Company commenced operations in April, 2008.
It is engaged in manufacturing and export of active pharmaceutical ingredients (APIs).
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development.

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Supriya Lifescience Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Supriya Lifescience Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 2,740 Cr while Market cap of Supriya Lifescience Ltd is 4,926 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Supriya Lifescience Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Supriya Lifescience Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Supriya Lifescience Ltd?

As of April 4, 2026, the Gujarat Themis Biosyn Ltd stock price is INR ₹251.5. On the other hand, Supriya Lifescience Ltd stock price is INR ₹612.1.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Supriya Lifescience Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Supriya Lifescience Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.